Indian stocks: Visit www.stage2stocks.com →

Cardiol Therapeutics Inc. Class A

Stage 2 · Advancing · week 10

As of Oct 22, 2026, Cardiol Therapeutics is in Stage 2, the uptrend phase, now in week 10 (since Aug 13, 2026). It closed at $1.15, 49.7% below its 52-week high and below its 200-day average, which is rising.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about the company

$1.15
-2.36% today
$140M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is CRDL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 33w
S4 28w
S4 27w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 8w → S3 10w → S2 33w → S3 6w → S2 2w → S3 6w → S4 28w → S1 8w → S2 3w → S3 3w → S4 27w → S1 3w → S2 9w → S3 7w → S2 10w current
Total tracked: 165 weeks across 15 stage runs.

CRDL among Drug Manufacturers - Specialty & Generic32nd of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…32CRDLStage 2 · wk 1050−35.0%
vs 52W High
-49.7%
$0.93 lo$2.29 hi
49.7% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
-11.5%
200 DMA: $1.30 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.29x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-35.0%
3M
-2.5%
6M
-15.4%
YTD
+15.7%
1Y
-5.0%
Scan Membership
Breakout Watch
Latest: 2024-09-23
7 appearances in last 60 days. First seen: 2020-02-11.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 10 · Vol 0.29x
2026-10-21S2
Wk 10 · Vol 0.38x
2026-10-20S2
Wk 10 · Vol 0.41x
2026-10-19S2
Wk 10 · Vol 0.41x
2026-10-16S2
Wk 10 · Vol 0.40x
2026-10-15S2
Wk 9 · Vol 0.40x
2026-10-14S2
Wk 9 · Vol 0.52x
2026-10-13S2
Wk 9 · Vol 1.30x
2026-10-12S2
Wk 9 · Vol 1.13x
2026-10-09S2
Wk 9 · Vol 0.82x
2026-10-08S2
Wk 8 · Vol 0.60x
2026-10-07S2
Wk 8 · Vol 2.52x
Moving averages & range
50 DMA
$1.71
200 DMA
$1.30
52W High
$2.29
52W Low
$0.93
5D Low
$1.10
Resistance levels (recent highs)
20d High
$1.71
60d High
$2.29
120d High
$2.29
250d High
$2.29
Next resistance
+48.7%
to 20d High
ROE
-190.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 7.8

Cardiol Therapeutics: quick answers

What stage is Cardiol Therapeutics in?

As of Oct 22, 2026, Cardiol Therapeutics (CRDL) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 13, 2026 and is in week 10. What the four stages mean

Is Cardiol Therapeutics in an uptrend?

Yes. Cardiol Therapeutics is in a Stage 2 uptrend. It trades 11.5% below its 200-day average, which is rising.

How far is Cardiol Therapeutics from its 52-week high?

Cardiol Therapeutics closed at $1.15 on Oct 22, 2026, 49.7% below its 52-week high of $2.29. Its 52-week low is $0.93.

How has Cardiol Therapeutics performed over the past year?

As of Oct 22, 2026, Cardiol Therapeutics is down 5.0% over the past year and up 15.7% so far in 2026.

Which sector and industry is Cardiol Therapeutics in?

Cardiol Therapeutics is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.